Evidence map›Paper›PMID 37568786›Full record

ArticleCancers2023

Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma: Association with Metabolic Tumor Burden Determined with FDG-PET/CT.

Antti Silvoniemi, Jukka Laine, Katri Aro, Linda Nissi, Leif Bäck, Jukka Schildt, Jussi Hirvonen, Jaana Hagström, Heikki Irjala, Leena-Maija Aaltonen and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Antti SilvoniemiDepartment of Otorhinolaryngology-Head and Neck Surgery, Turku University Hospital, University of Turku, FI-20521 Turku, Finland.ORCID 0000-0001-9655-1410
Jukka LaineDepartment of Pathology, Turku University Hospital, University of Turku, FI-20520 Turku, Finland.
Katri AroDepartment of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital, University of Helsinki, FI-00029 Helsinki, Finland.ORCID 0000-0001-8103-5237
Linda NissiDepartment of Oncology, Turku University Hospital, University of Turku, FI-20521 Turku, Finland.
Leif BäckDepartment of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital, University of Helsinki, FI-00029 Helsinki, Finland.
Jukka SchildtDepartment of Nuclear Medicine, HUS Diagnostic Center, Helsinki University Hospital, University of Helsinki, FI-00029 Helsinki, Finland.ORCID 0000-0003-3773-8001
Jussi HirvonenDepartment of Radiology, Turku University Hospital, University of Turku, FI-20521 Turku, Finland.ORCID 0000-0002-0368-3746
Jaana HagströmDepartment of Oral Pathology and Radiology, University of Turku, FI-20520 Turku, Finland.ORCID 0000-0001-6079-7881
Heikki IrjalaDepartment of Otorhinolaryngology-Head and Neck Surgery, Turku University Hospital, University of Turku, FI-20521 Turku, Finland.ORCID 0000-0003-3054-4677
Leena-Maija AaltonenDepartment of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital, University of Helsinki, FI-00029 Helsinki, Finland.
Marko SeppänenTurku PET Centre, University of Turku, FI-20521 Turku, Finland.
Heikki MinnTurku PET Centre, University of Turku, FI-20521 Turku, Finland.
University of Turku · FIUniversity of Helsinki · FI

Funding

Cancer Society of Finland NAFinnish Government Research Funds NAFinnish Medical Foundation NAHelsinki University Research Funds NAThe Finnish ORL-HNS Foundation NA
6 · The paper itself

Abstract

backgroundThe detection of circulating tumor DNA (ctDNA) with next-generation sequencing (NGS) in venous blood is a promising tool for the genomic profiling of head and neck squamous cell carcinoma (HNSCC). The association between ctDNA findings and metabolic tumor burden detected with FDG-PET/CT imaging is of particular interest for developing prognostic and predictive algorithms in HNSCC.

methodsTwenty-six prospectively enrolled HNSCC patients were eligible for further analysis. All patients underwent tumor tissue and venous liquid biopsy sampling and FDG-PET/CT before definitive oncologic treatment. An NGS-based commercial panel was used for a genomic analysis of the samples.

resultsMaximum variant allele frequency (VAF) in blood correlated positively with whole-body (WB) metabolic tumor volume (MTV) and total lesion glycolysis (TLG) (r = 0.510,

conclusionsA high metabolic tumor burden based on FDG imaging is associated with a positive liquid biopsy and high maximum VAF. Our findings suggest a complementary role of metabolic and genomic signatures in the pre-treatment evaluation of HNSCC.

Indexed as

cfDNAcirculating tumor DNActDNAFDG-PET/CThead and neck cancerliquid biopsymetabolic tumor volumenext-generation sequencingtotal lesion glycolysisvariant allele frequency

Identifiers

PMID37568786
PMCPMC10416934
OpenAlexW4385577082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.